Vos Ad, Conzelmann Karl-Klaus, Finke Stefan, Müller Thomas, Teifke Jens, Fooks Anthony R, Neubert Andreas
IDT Biologika GmbH, Am Pharmapark, 06855 Dessau-Rosslau, Germany.
Adv Prev Med. 2011;2011:898171. doi: 10.4061/2011/898171. Epub 2011 Sep 21.
Different approaches have been applied to develop highly attenuated rabies virus vaccines for oral vaccination of mesocarnivores. One prototype vaccine construct is SAD dIND1, which contains a deletion in the P-gene severely limiting the inhibition of type-1 interferon induction. Immunogenicity studies in foxes and skunks were undertaken to investigate whether this highly attenuated vaccine would be more immunogenic than the parental SAD B19 vaccine strain. In foxes, it was demonstrated that SAD dIND1 protected the animals against a rabies infection after a single oral dose, although virus neutralizing antibody titres were lower than in foxes orally vaccinated with the SAD B19 virus as observed in previous experiments. In contrast, skunks receiving 10(7.5) FFU SAD dIND1 did not develop virus neutralizing antibodies and were not protected against a subsequent rabies infection.
已经采用了不同方法来开发用于中肉食性动物口服疫苗接种的高度减毒狂犬病病毒疫苗。一种原型疫苗构建体是SAD dIND1,其P基因中有一个缺失,严重限制了1型干扰素诱导的抑制作用。开展了狐狸和臭鼬的免疫原性研究,以调查这种高度减毒疫苗是否比亲本SAD B19疫苗株具有更强的免疫原性。在狐狸中,结果表明,SAD dIND1单次口服剂量后能保护动物免受狂犬病感染,尽管病毒中和抗体滴度低于先前实验中口服接种SAD B19病毒的狐狸。相比之下,接受10(7.5) FFU SAD dIND1的臭鼬未产生病毒中和抗体,也未受到后续狂犬病感染的保护。